NEW YORK, Dec. 30, 2021 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the
"Company"), a leading biotech company developing
psychedelic-inspired therapies, today announced that MindMed's
Chief Executive Officer and Director, Robert Barrow, will be participating in a panel
and in one-on-one investor meetings at the LifeSci Partners
11th Annual Corporate Access Event, to be held virtually
January 5-7, 2022.
Details on the panel discussion can be found below.
Topic: "Psychedelics: More Than Just
a Trip"
Date: Wednesday, January 5, 2022
Time: 10:00 AM
ET
Webcast link: Click Here
A replay link of the panel discussion will also be available on
MindMed's website.
About MindMed
MindMed is a clinical-stage biotech company that seeks to
discover, develop and deploy psychedelic-inspired medicines and
therapies to address mental health and addiction. The Company is
assembling a compelling drug development pipeline of innovative
treatments based on psychedelic substances including psilocybin,
LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed
executive team brings extensive biopharmaceutical experience to
MindMed's approach to developing the next generation of
psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-at-the-lifesci-partners-11th-annual-corporate-access-event-301451687.html
SOURCE Mind Medicine (MindMed) Inc.